Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome

S. Jean Hsieh, Hanjing Zhuo, Neal L. Benowitz, B. Taylor Thompson, Kathleen D. Liu, Michael A. Matthay, Carolyn S. Calfee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

OBJECTIVES:: Cigarette smoke exposure has recently been found to be associated with increased susceptibility to trauma-and transfusion-associated acute respiratory distress syndrome. We sought to determine 1) the incidence of cigarette smoke exposure in a diverse multicenter sample of acute respiratory distress syndrome patients and 2) whether cigarette smoke exposure is associated with severity of lung injury and mortality in acute respiratory distress syndrome. DESIGN:: Analysis of the Albuterol for the Treatment of Acute Lung Injury and Omega Acute Respiratory Distress Syndrome Network studies. SETTING:: Acute Respiratory Distress Syndrome Network hospitals. PATIENTS:: Three hundred eighty-one patients with acute respiratory distress syndrome. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanol, a validated tobacco-specific marker, was measured in urine samples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network randomized controlled trials. Urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels were consistent with active smoking in 36% of acute respiratory distress syndrome patients and with passive smoking in 41% of nonsmokers (vs 20% and 40% in general population, respectively). Patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels in the active smoking range were younger and had a higher incidence of alcohol misuse, fewer comorbidities, lower severity of illness, and less septic shock at enrollment compared with patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels. Despite this lower severity of illness, the severity of lung injury did not significantly differ based on biomarker-determined smoking status. Cigarette smoke exposure was not significantly associated with death after adjusting for differences in age, alcohol use, comorbidities, and severity of illness. CONCLUSIONS:: In this first multicenter study of biomarker-determined cigarette smoke exposure in acute respiratory distress syndrome patients, we found that active cigarette smoke exposure was significantly more prevalent among acute respiratory distress syndrome patients compared to population averages. Despite their younger age, better overall health, and lower severity of illness, smokers by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol had similar severity of lung injury as patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol. These findings suggest that active cigarette smoking may increase susceptibility to acute respiratory distress syndrome in younger, healthier patients.

Original languageEnglish (US)
Pages (from-to)2058-2068
Number of pages11
JournalCritical Care Medicine
Volume42
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Tobacco Smoke Pollution
Adult Respiratory Distress Syndrome
Smoking
Smoke
Tobacco Products
Lung Injury
Comorbidity
Biomarkers
Alcohols
Urine
National Heart, Lung, and Blood Institute (U.S.)
Albuterol
Acute Lung Injury
Incidence
Septic Shock
Population
Multicenter Studies
Tobacco
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol
Randomized Controlled Trials

Keywords

  • 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
  • acute respiratory distress syndrome
  • cigarette smoking
  • lung injury
  • mortality

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Hsieh, S. J., Zhuo, H., Benowitz, N. L., Thompson, B. T., Liu, K. D., Matthay, M. A., & Calfee, C. S. (2014). Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome. Critical Care Medicine, 42(9), 2058-2068. https://doi.org/10.1097/CCM.0000000000000418

Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome. / Hsieh, S. Jean; Zhuo, Hanjing; Benowitz, Neal L.; Thompson, B. Taylor; Liu, Kathleen D.; Matthay, Michael A.; Calfee, Carolyn S.

In: Critical Care Medicine, Vol. 42, No. 9, 2014, p. 2058-2068.

Research output: Contribution to journalArticle

Hsieh, SJ, Zhuo, H, Benowitz, NL, Thompson, BT, Liu, KD, Matthay, MA & Calfee, CS 2014, 'Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome', Critical Care Medicine, vol. 42, no. 9, pp. 2058-2068. https://doi.org/10.1097/CCM.0000000000000418
Hsieh, S. Jean ; Zhuo, Hanjing ; Benowitz, Neal L. ; Thompson, B. Taylor ; Liu, Kathleen D. ; Matthay, Michael A. ; Calfee, Carolyn S. / Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome. In: Critical Care Medicine. 2014 ; Vol. 42, No. 9. pp. 2058-2068.
@article{f7e6f4332a5c44f6b8f8b01c564526cd,
title = "Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome",
abstract = "OBJECTIVES:: Cigarette smoke exposure has recently been found to be associated with increased susceptibility to trauma-and transfusion-associated acute respiratory distress syndrome. We sought to determine 1) the incidence of cigarette smoke exposure in a diverse multicenter sample of acute respiratory distress syndrome patients and 2) whether cigarette smoke exposure is associated with severity of lung injury and mortality in acute respiratory distress syndrome. DESIGN:: Analysis of the Albuterol for the Treatment of Acute Lung Injury and Omega Acute Respiratory Distress Syndrome Network studies. SETTING:: Acute Respiratory Distress Syndrome Network hospitals. PATIENTS:: Three hundred eighty-one patients with acute respiratory distress syndrome. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanol, a validated tobacco-specific marker, was measured in urine samples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network randomized controlled trials. Urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels were consistent with active smoking in 36{\%} of acute respiratory distress syndrome patients and with passive smoking in 41{\%} of nonsmokers (vs 20{\%} and 40{\%} in general population, respectively). Patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels in the active smoking range were younger and had a higher incidence of alcohol misuse, fewer comorbidities, lower severity of illness, and less septic shock at enrollment compared with patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels. Despite this lower severity of illness, the severity of lung injury did not significantly differ based on biomarker-determined smoking status. Cigarette smoke exposure was not significantly associated with death after adjusting for differences in age, alcohol use, comorbidities, and severity of illness. CONCLUSIONS:: In this first multicenter study of biomarker-determined cigarette smoke exposure in acute respiratory distress syndrome patients, we found that active cigarette smoke exposure was significantly more prevalent among acute respiratory distress syndrome patients compared to population averages. Despite their younger age, better overall health, and lower severity of illness, smokers by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol had similar severity of lung injury as patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol. These findings suggest that active cigarette smoking may increase susceptibility to acute respiratory distress syndrome in younger, healthier patients.",
keywords = "4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, acute respiratory distress syndrome, cigarette smoking, lung injury, mortality",
author = "Hsieh, {S. Jean} and Hanjing Zhuo and Benowitz, {Neal L.} and Thompson, {B. Taylor} and Liu, {Kathleen D.} and Matthay, {Michael A.} and Calfee, {Carolyn S.}",
year = "2014",
doi = "10.1097/CCM.0000000000000418",
language = "English (US)",
volume = "42",
pages = "2058--2068",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome

AU - Hsieh, S. Jean

AU - Zhuo, Hanjing

AU - Benowitz, Neal L.

AU - Thompson, B. Taylor

AU - Liu, Kathleen D.

AU - Matthay, Michael A.

AU - Calfee, Carolyn S.

PY - 2014

Y1 - 2014

N2 - OBJECTIVES:: Cigarette smoke exposure has recently been found to be associated with increased susceptibility to trauma-and transfusion-associated acute respiratory distress syndrome. We sought to determine 1) the incidence of cigarette smoke exposure in a diverse multicenter sample of acute respiratory distress syndrome patients and 2) whether cigarette smoke exposure is associated with severity of lung injury and mortality in acute respiratory distress syndrome. DESIGN:: Analysis of the Albuterol for the Treatment of Acute Lung Injury and Omega Acute Respiratory Distress Syndrome Network studies. SETTING:: Acute Respiratory Distress Syndrome Network hospitals. PATIENTS:: Three hundred eighty-one patients with acute respiratory distress syndrome. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanol, a validated tobacco-specific marker, was measured in urine samples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network randomized controlled trials. Urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels were consistent with active smoking in 36% of acute respiratory distress syndrome patients and with passive smoking in 41% of nonsmokers (vs 20% and 40% in general population, respectively). Patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels in the active smoking range were younger and had a higher incidence of alcohol misuse, fewer comorbidities, lower severity of illness, and less septic shock at enrollment compared with patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels. Despite this lower severity of illness, the severity of lung injury did not significantly differ based on biomarker-determined smoking status. Cigarette smoke exposure was not significantly associated with death after adjusting for differences in age, alcohol use, comorbidities, and severity of illness. CONCLUSIONS:: In this first multicenter study of biomarker-determined cigarette smoke exposure in acute respiratory distress syndrome patients, we found that active cigarette smoke exposure was significantly more prevalent among acute respiratory distress syndrome patients compared to population averages. Despite their younger age, better overall health, and lower severity of illness, smokers by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol had similar severity of lung injury as patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol. These findings suggest that active cigarette smoking may increase susceptibility to acute respiratory distress syndrome in younger, healthier patients.

AB - OBJECTIVES:: Cigarette smoke exposure has recently been found to be associated with increased susceptibility to trauma-and transfusion-associated acute respiratory distress syndrome. We sought to determine 1) the incidence of cigarette smoke exposure in a diverse multicenter sample of acute respiratory distress syndrome patients and 2) whether cigarette smoke exposure is associated with severity of lung injury and mortality in acute respiratory distress syndrome. DESIGN:: Analysis of the Albuterol for the Treatment of Acute Lung Injury and Omega Acute Respiratory Distress Syndrome Network studies. SETTING:: Acute Respiratory Distress Syndrome Network hospitals. PATIENTS:: Three hundred eighty-one patients with acute respiratory distress syndrome. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanol, a validated tobacco-specific marker, was measured in urine samples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network randomized controlled trials. Urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels were consistent with active smoking in 36% of acute respiratory distress syndrome patients and with passive smoking in 41% of nonsmokers (vs 20% and 40% in general population, respectively). Patients with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels in the active smoking range were younger and had a higher incidence of alcohol misuse, fewer comorbidities, lower severity of illness, and less septic shock at enrollment compared with patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol levels. Despite this lower severity of illness, the severity of lung injury did not significantly differ based on biomarker-determined smoking status. Cigarette smoke exposure was not significantly associated with death after adjusting for differences in age, alcohol use, comorbidities, and severity of illness. CONCLUSIONS:: In this first multicenter study of biomarker-determined cigarette smoke exposure in acute respiratory distress syndrome patients, we found that active cigarette smoke exposure was significantly more prevalent among acute respiratory distress syndrome patients compared to population averages. Despite their younger age, better overall health, and lower severity of illness, smokers by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol had similar severity of lung injury as patients with undetectable 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol. These findings suggest that active cigarette smoking may increase susceptibility to acute respiratory distress syndrome in younger, healthier patients.

KW - 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol

KW - acute respiratory distress syndrome

KW - cigarette smoking

KW - lung injury

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84906791095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906791095&partnerID=8YFLogxK

U2 - 10.1097/CCM.0000000000000418

DO - 10.1097/CCM.0000000000000418

M3 - Article

VL - 42

SP - 2058

EP - 2068

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 9

ER -